Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations

World Journal of Gastroenterology

Volumn 20, Issue 28, 2014, Pages 9330-9337

  Milić, Sandra ^a   Lulić, Davorka ^a   Štimac, Davor ^a  

^a KBC RIJEKA   (Croatia)

Author keywords

Fatty liver; Insulin resistance; Intra abdominal fat; Metabolism; Non alcoholic fatty liver disease; Obesity

Indexed keywords

ADIPOCYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN;

ADIPOSE TISSUE; ARTICLE; BIOCHEMISTRY; BODY MASS; CLINICAL FEATURE; COMORBIDITY; CYTOKINE RELEASE; DISEASE COURSE; DYSPEPSIA; FATIGUE; HEPATOSPLENOMEGALY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPOGENESIS; LIVER INJURY; LIVER PAIN; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PORTAL VEIN; PREVALENCE; WEIGHT REDUCTION; ANIMAL; LIPID METABOLISM; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADIPOSE TISSUE; ADIPOSITY; ANIMALS; HUMANS; LIPID METABOLISM; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84908871564     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i28.9330     Document Type: Article

References (101)

1. Mavrogiannaki AN, Migdalis IN. Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. Int J Endocrinol 2013; 2013: 450639 [PMID: 23653642 DOI: 10.1155/2013/450639]
2. Milić S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 2012; 30: 158-162 [PMID: 22722431 DOI: 10.1159/000336669]
3. Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009; 41: 615-625 [PMID: 19223251 DOI: 10.1016/j.dld.2009.01.004]
4. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344-353 [PMID: 21520200 DOI: 10.1002/hep.24376]
5. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term followup of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873 [PMID: 17006923 DOI: 10.1002/hep.21327]
6. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10: 1342-1359.e2 [PMID: 23041539 DOI: 10.1016/j.cgh.2012.10.00]
7. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669 [PMID: 10051466 DOI: 10.1002/hep.510290347]
8. Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, Hardies J, Cusi K. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 2012; 35: 873-878 [PMID: 22374640 DOI: 10.2337/dc11-1849]
9. Souza MR, Diniz Mde F, Medeiros-Filho JE, Araújo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 2012; 49: 89-96 [PMID: 22481692 DOI: 10.1590/S0004-28032012000100015]
10. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10: 330-344 [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41]
11. Lonardo A, Sookoian S, Chonchol M, Loria P, Targher G. Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des 2013; 19: 5177-5192 [PMID: 23432668 DOI: 10.2174/13816128130301]
12. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010; 42: 320-330 [PMID: 20207596 DOI: 10.1016/j.dld.2010.01.016]
13. Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 2009; 6: 236-247 [PMID: 19347015 DOI: 10.1038/nrgastro.2009.33]
14. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x]
15. Kubik JF, Gill RS, Laffin M, Karmali S. The impact of bariatric surgery on psychological health. J Obes 2013; 2013: 837989 [PMID: 23606952 DOI: 10.1155/2013/83798]
16. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii, 1-253 [PMID: 11234459]
17. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet 2011; 377: 557-567 [PMID: 21295846 DOI: 10.1016/S0140-6736(10)62037-5]
18. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA 2003; 289: 187-193 [PMID: 12517229 DOI: 10.1001/jama.289.2.187]
19. Kaplan MS, Huguet N, Newsom JT, McFarland BH, Lindsay J. Prevalence and correlates of overweight and obesity among older adults: findings from the Canadian National Population Health Survey. J Gerontol A Biol Sci Med Sci 2003; 58: 1018-1030 [PMID: 14630884 DOI: 10.1093/gerona/58.11. M1018]
20. Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012; 56: 952-964 [PMID: 22173168 DOI: 10.1016/j.jhep.2011.08.025]
21. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131 [PMID: 20858492 DOI: 10.1053/j.gastro.2010.09.038]
22. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117 [PMID: 10644271 DOI: 10.7326/0003-4819-132-2-200001180-00004]
23. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, Norris HT, Caro JF. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990; 85: 1349-1355 [PMID: 2220728]
24. Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord 2004; 28: 167-172 [PMID: 14610526 DOI: 10.1038/sj.ijo.0802519]
25. Thamer C, Machann J, Haap M, Stefan N, Heller E, Schnödt B, Stumvoll M, Claussen C, Fritsche A, Schick F, Häring H. Intrahepatic lipids are predicted by visceral adipose tissue mass in healthy subjects. Diabetes Care 2004; 27: 2726-2729 [PMID: 15505012 DOI: 10.2337/diacare.27.11.2726]
26. Mårin P, Andersson B, Ottosson M, Olbe L, Chowdhury B, Kvist H, Holm G, Sjöström L, Björntorp P. The morphology and metabolism of intraabdominal adipose tissue in men. Metabolism 1992; 41: 1242-1248 [PMID: 1435298 DOI: 10.1016/0026-0495(92)90016-4]
27. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, Machicao F, Fritsche A, Häring HU. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008; 168: 1609-1616 [PMID: 18695074 DOI: 10.1001/archinte.168.15.1609]
28. Stefan N, Häring HU. The metabolically benign and malignant fatty liver. Diabetes 2011; 60: 2011-2017 [PMID: 21788578 DOI: 10.2337/db11-0231]
29. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver - the link between adipocytes and hepatocytes. Digestion 2011; 83: 124-133 [PMID: 21042023 DOI: 10.1159/000318741]
30. Lonardo A, Caldwell SH, Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Rev Endocrinol Metab 2010; 5: 403-423 [DOI: 10.1586/eem.10.5]
31. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-190 [PMID: 15685173 DOI: 10.1038/nm1166]
32. Boden G, She P, Mozzoli M, Cheung P, Gumireddy K, Reddy P, Xiang X, Luo Z, Ruderman N. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes 2005; 54: 3458-3465 [PMID: 16306362 DOI: 10.2337/diabetes.54.12.3458]
33. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494-1505 [PMID: 16691291 DOI: 10.1172/JCI26498]
34. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008; 118: 829-838 [PMID: 18317565 DOI: 10.1172/JCI34275]
35. Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, Morino K, Kim S, Distefano A, Samuel VT, Neschen S, Zhang D, Wang A, Zhang XM, Kahn M, Cline GW, Pandey SK, Geisler JG, Bhanot S, Monia BP, Shulman GI. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem 2007; 282: 22678-22688 [PMID: 17526931 DOI: 10.1074/jbc.M704213200]
36. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45: 1366-1374 [PMID: 17476695 DOI: 10.1002/hep.21655]
37. Ueki K, Kondo T, Tseng YH, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 2004; 101: 10422-10427 [PMID: 15240880 DOI: 10.1073/pnas.0402511101]
38. Sabio G, Das M, Mora A, Zhang Z, Jun JY, Ko HJ, Barrett T, Kim JK, Davis RJ. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008; 322: 1539-1543 [PMID: 19056984 DOI: 10.1126/science.1160794]
39. Quehenberger O, Dennis EA. The human plasma lipidome. N Engl J Med 2011; 365: 1812-1823 [PMID: 22070478 DOI: 10.1056/NEJMra1104901]
40. Monsour HP, Frenette CT, Wyne K. Fatty liver: a link to cardiovascular disease-its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J 2012; 8: 21-25 [PMID: 23227282]
41. Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol 2011; 17: 2801-2811 [PMID: 21734787 DOI: 10.3748/wjg. v17.i23.2801]
42. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 1999; 130: 671-680 [PMID: 10215564 DOI: 10.7326/0003-4819-130-8-199904200-00014]
43. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, Liddle C, Samarasinghe D, George J. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002; 36: 403-409 [PMID: 12143049 DOI: 10.1053/jhep.2002.34738]
44. Huang XD, Fan Y, Zhang H, Wang P, Yuan JP, Li MJ, Zhan XY. Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. World J Gastroenterol 2008; 14: 2888-2893 [PMID: 18473416 DOI: 10.3748/wjg.14.2888]
45. Wang J, Leclercq I, Brymora JM, Xu N, Ramezani-Moghadam M, London RM, Brigstock D, George J. Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology 2009; 137: 713-723 [PMID: 19375424 DOI: 10.1053/j.gastro.2009.04.01]
46. Biddinger SB, Miyazaki M, Boucher J, Ntambi JM, Kahn CR. Leptin suppresses stearoyl-CoA desaturase 1 by mechanisms independent of insulin and sterol regulatory elementbinding protein-1c. Diabetes 2006; 55: 2032-2041 [PMID: 16804073 DOI: 10.2337/db05-0742]
47. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808 [PMID: 14679176 DOI: 10.1172/JCI19246]
48. Zoico E, Garbin U, Olioso D, Mazzali G, Fratta Pasini AM, Di Francesco V, Sepe A, Cominacini L, Zamboni M. The effects of adiponectin on interleukin-6 and MCP-1 secretion in lipopolysaccharide-treated 3T3-L1 adipocytes: role of the NF-kappaB pathway. Int J Mol Med 2009; 24: 847-851 [PMID: 19885628 DOI: 10.3892/ijmm-00000302]
49. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, Gentilcore E, Natale S, Cassader M, Rizzetto M, Pasquali R, Marchesini G. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90: 3498-3504 [PMID: 15797948 DOI: 10.1210/jc.2004-2240]
50. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc Cc, Itani SI, Lodish HF, Ruderman NB. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002; 99: 16309-16313 [PMID: 12456889 DOI: 10.1073/pnas.222657499]
51. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100 [PMID: 12840063 DOI: 10.1172/JCI17797]
52. Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207-210 [PMID: 16401483 DOI: 10.1053/j.gastro.2005.11.017]
53. Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 1998; 42: 2-7 [PMID: 9505873 DOI: 10.1136/gut.42.1.2]
54. Mezey E, Imbembo AL, Potter JJ, Rent KC, Lombardo R, Holt PR. Endogenous ethanol production and hepatic disease following jejunoileal bypass for morbid obesity. Am J Clin Nutr 1975; 28: 1277-1283 [PMID: 1190105]
55. Billiar TR, Maddaus MA, West MA, Curran RD, Wells CA, Simmons RL. Intestinal gram-negative bacterial overgrowth in vivo augments the in vitro response of Kupffer cells to endotoxin. Ann Surg 1988; 208: 532-540 [PMID: 3052329 DOI: 10.1097/00000658-198810000-00015]
56. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003; 38: 681-687 [PMID: 12713883 DOI: 10.1016/S0168-8278(03)00097-7]
57. Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G, Donnini D, Faggian D, Mussap M, Plebani M, Avellini C, Federspil G, Sechi LA, Vettor R. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006; 91: 1081-1086 [PMID: 16394091 DOI: 10.1210/jc.2005-1056]
58. Aller R, de Luis DA, Izaola O, Sagrado MG, Conde R, Velasco MC, Alvarez T, Pacheco D, González JM. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci 2009; 54: 1772-1777 [PMID: 19005759 DOI: 10.1007/s10620-008-0539-9]
59. Yilmaz Y, Yonal O, Kurt R, Alahdab YO, Eren F, Ozdogan O, Celikel CA, Imeryuz N, Kalayci C, Avsar E. Serum levels of omentin, chemerin and adipsin in patients with biopsyproven nonalcoholic fatty liver disease. Scand J Gastroenterol 2011; 46: 91-97 [PMID: 20809771 DOI: 10.3109/00365521.201 0.516452]
60. Mirza MS. Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterol 2011; 2011: 592404 [PMID: 21991518 DOI: 10.5402/2011/592404]
61. Asaoka Y, Terai S, Sakaida I, Nishina H. The expanding role of fish models in understanding non-alcoholic fatty liver disease. Dis Model Mech 2013; 6: 905-914 [PMID: 23720231 DOI: 10.1242/dmm.011981]
62. Koutsari C, Jensen MD. Thematic review series: patientoriented research. Free fatty acid metabolism in human obesity. J Lipid Res 2006; 47: 1643-1650 [PMID: 16685078 DOI: 10.1194/jlr.R600011-JLR200]
63. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-1351 [PMID: 15864352 DOI: 10.1172/JCI23621]
64. Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of Fatty liver. Endocr Rev 2008; 29: 939-960 [PMID: 18723451 DOI: 10.1210/er.2008-0009]
65. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest 2004; 113: 1582-1588 [PMID: 15173884 DOI: 10.1172/JCI21047]
66. Parks EJ, Hellerstein MK. Thematic review series: patientoriented research. Recent advances in liver triacylglycerol and fatty acid metabolism using stable isotope labeling techniques. J Lipid Res 2006; 47: 1651-1660 [PMID: 16741290 DOI: 10.1194/jlr.R600018-JLR200]
67. Ehehalt R, Füllekrug J, Pohl J, Ring A, Herrmann T, Stremmel W. Translocation of long chain fatty acids across the plasma membrane-lipid rafts and fatty acid transport proteins. Mol Cell Biochem 2006; 284: 135-140 [PMID: 16477381 DOI: 10.1007/s11010-005-9034-1]
68. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006; 55 Suppl 2: S9-S15 [PMID: 17130651 DOI: 10.2337/db06-S002]
69. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119 [PMID: 15864338 DOI: 10.1172/JCI25102]
70. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 3015-3025 [PMID: 17053832 DOI: 10.1172/JCI28898]
71. Knebel B, Haas J, Hartwig S, Jacob S, Köllmer C, Nitzgen U, Muller-Wieland D, Kotzka J. Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass. PLoS One 2012; 7: e31812 [PMID: 22363740 DOI: 10.1371/journal.pone.003181]
72. Schwarz JM, Linfoot P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003; 77: 43-50 [PMID: 12499321]
73. Parks EJ, Krauss RM, Christiansen MP, Neese RA, Hellerstein MK. Effects of a low-fat, high-carbohydrate diet on VLDLtriglyceride assembly, production, and clearance. J Clin Invest 1999; 104: 1087-1096 [PMID: 10525047 DOI: 10.1172/JCI6572]
74. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-229 [PMID: 11943743 DOI: 10.1210/er.23.2.201]
75. Kim LJ, Nalls MA, Eiriksdottir G, Sigurdsson S, Launer LJ, Koster A, Chaves PH, Jonsdottir B, Garcia M, Gudnason V, Harris TB. Associations of visceral and liver fat with the metabolic syndrome across the spectrum of obesity: the AGES-Reykjavik study. Obesity (Silver Spring) 2011; 19: 1265-1271 [PMID: 21183935 DOI: 10.1038/oby.2010.291]
76. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-3028 [PMID: 12107194 DOI: 10.1210/jc.87.7.3023]
77. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, Feigenbaum L, Lee E, Aoyama T, Eckhaus M, Reitman ML, Vinson C. Life without white fat: a transgenic mouse. Genes Dev 1998; 12: 3168-3181 [PMID: 9784492 DOI: 10.1101/gad.12.20.3168]
78. Agarwal AK, Garg A. Congenital generalized lipodystrophy: significance of triglyceride biosynthetic pathways. Trends Endocrinol Metab 2003; 14: 214-221 [PMID: 12826327 DOI: 10.1016/S1043-2760(03)00078-X]
79. Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res 2013; 43: 51-64 [PMID: 23332087 DOI: 10.1111/j.1872-034X.2012.01031.x]
80. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867 [PMID: 17167474 DOI: 10.1038/nature05485]
81. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801 [PMID: 16823477 DOI: 10.1172/JCI29069]
82. Muoio DM, Newgard CB. Biomedicine. Insulin resistance takes a trip through the ER. Science 2004; 306: 425-426 [PMID: 15486283 DOI: 10.1126/science.1104680]
83. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192 [PMID: 11266382 DOI: 10.1053/gast.2001.23256]
84. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005; 42: 928-940 [PMID: 15885365 DOI: 10.1016/j.jhep.2005.03.004]
85. Lonardo A, Carani C, Carulli N, Loria P. 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol 2006; 44: 1196-1207 [PMID: 16618516 DOI: 10.1016/j.jhep.2006.03.005]
86. Gao X, Fan JG. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. J Diabetes 2013; 5: 406-415 [PMID: 23560695 DOI: 10.1111/1753-0407.12056]
87. Attar BM, Van Thiel DH. Current concepts and management approaches in nonalcoholic fatty liver disease. Scientific World Journal 2013; 2013: 481893 [PMID: 23576902 DOI: 10.1155/2013/481893]
88. Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92: 3490-3497 [PMID: 17595248 DOI: 10.1210/jc.2007-0482]
89. Marchesini G, Avagnina S, Barantani EG, Ciccarone AM, Corica F, Dall'Aglio E, Dalle Grave R, Morpurgo PS, Tomasi F, Vitacolonna E. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest 2005; 28: 333-339 [PMID: 15966506]
90. Thamer C, Tschritter O, Haap M, Shirkavand F, Machann J, Fritsche A, Schick F, Häring H, Stumvoll M. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res 2005; 37: 246-251 [PMID: 15952086 DOI: 10.1055/s-2005-861411]
91. Stranges S, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M, Nochajski TH, Trevisan M. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology 2004; 39: 754-763 [PMID: 14999694 DOI: 10.1002/hep.20149]
92. Targher G, Bertolini L, Scala L, Poli F, Zenari L, Falezza G. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxf) 2004; 61: 700-703 [PMID: 15579183 DOI: 10.1111/j.1365-2265.2004.02151.x]
93. Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, Tsutsumi M, Takase S. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 2007; 102: 1931-1938 [PMID: 17511754 DOI: 10.1111/j.1572-0241.2007.01322.x]
94. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, Muggeo M, Day CP. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008; 16: 1394-1399 [PMID: 18369343 DOI: 10.1038/oby.2008.64]
95. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013; 58: 120-127 [PMID: 23401313 DOI: 10.1002/hep.26319]
96. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462-E468 [PMID: 15339742 DOI: 10.1152/ajpendo.00064.2004]
97. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009; 51: 1061-1067 [PMID: 19846234 DOI: 10.1016/j.jhep.2009.09.00]
98. Ciupińska-Kajor M, Hartleb M, Kajor M, Kukla M, Wyleżoł M, Lange D, Liszka L. Hepatic angiogenesis and fibrosis are common features in morbidly obese patients. Hepatol Int 2013; 7: 233-240 [PMID: 23519653 DOI: 10.1007/s12072-011-9320-9]
99. Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance? J Obes 2013; 2013: 839275 [PMID: 23431426 DOI: 10.1155/2013/839275]
100. Vargas V, Allende H, Lecube A, Salcedo MT, Baena-Fustegueras JA, Fort JM, Rivero J, Ferrer R, Catalán R, Pardina E, Ramón Y Cajal S, Guardia J, Peinado-Onsurbe J. Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients. World J Hepatol 2012; 4: 382-388 [PMID: 23355916 DOI: 10.4254/wjh. v4.i12.382]
101. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679-689 [PMID: 20041406 DOI: 10.1002/hep.23280]